BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smith SM, Wachter K, Burris HA, Schilsky RL, George DJ, Peterson DE, Johnson ML, Markham MJ, Mileham KF, Beg MS, Bendell JC, Dreicer R, Keedy VL, Kimple RJ, Knoll MA, Loconte N, Mackay H, Meisel JL, Moynihan TJ, Mulrooney DA, Mulvey TM, Odenike O, Pennell NA, Reeder-hayes K, Smith C, Sullivan RJ, Uzzo R. Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. JCO 2021;39:1165-84. [DOI: 10.1200/jco.20.03420] [Cited by in Crossref: 5] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Garattini SK, Valent F, Minisini AM, Riosa C, Favaretti C, Regattin L, Fasola G. Analysis of workload generated in the two years following first consultation by each new cancer patient: studying the past to plan the future of cancer care. BMC Health Serv Res 2022;22:1184. [PMID: 36131286 DOI: 10.1186/s12913-022-08573-3] [Reference Citation Analysis]
2 Didamson OC, Chandran R, Abrahamse H. A Gold Nanoparticle Bioconjugate Delivery System for Active Targeted Photodynamic Therapy of Cancer and Cancer Stem Cells. Cancers 2022;14:4558. [DOI: 10.3390/cancers14194558] [Reference Citation Analysis]
3 Modi N, Danell N, Perry R, Abuhelwa A, Rathod A, Badaoui S, Mckinnon R, Haseloff M, Shahnam A, Swain S, Welslau M, Sorich M, Hopkins A. Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer. ESMO Open 2022;7:100475. [DOI: 10.1016/j.esmoop.2022.100475] [Reference Citation Analysis]
4 Myer NM, Shitara K, Chung HC, Lordick F, Kelly RJ, Szabo Z, Cao ZA, Leong S, Ilson DH, Weichert W. Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer. J Cancer Res Clin Oncol 2022. [PMID: 35551464 DOI: 10.1007/s00432-021-03902-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Mudhish EA, Siddique AB, Ebrahim HY, Abdelwahed KS, King JA, El Sayed KA. The Tobacco β-Cembrenediol: A Prostate Cancer Recurrence Suppressor Lead and Prospective Scaffold via Modulation of Indoleamine 2,3-Dioxygenase and Tryptophan Dioxygenase. Nutrients 2022;14:1505. [DOI: 10.3390/nu14071505] [Reference Citation Analysis]
6 Miyai Y, Sugiyama D, Hase T, Asai N, Taki T, Nishida K, Fukui T, Chen-Yoshikawa TF, Kobayashi H, Mii S, Shiraki Y, Hasegawa Y, Nishikawa H, Ando Y, Takahashi M, Enomoto A. Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade. Life Sci Alliance 2022;5:e202101230. [PMID: 35236758 DOI: 10.26508/lsa.202101230] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Stefanska B, Tucker SJ, MacEwan DJ. Themed issue: 'New avenues in cancer prevention and treatment'. Br J Pharmacol 2022. [PMID: 35146753 DOI: 10.1111/bph.15715] [Reference Citation Analysis]
8 Li X, Zhou H, Huang W, Wang X, Meng M, Hou Z, Liao L, Tang W, Xie Y, Wang R, Yu H, Wang L, Zhu H, Wang W, Tan J, Li R. Retrospective analysis of the efficacy of adjuvant cytokine‐induced killer cell immunotherapy combined with chemotherapy in colorectal cancer patients after surgery. Clin & Trans Imm 2022;11. [DOI: 10.1002/cti2.1368] [Reference Citation Analysis]
9 Huang A, Yang Y, Shi JY, Li YK, Xu JX, Cheng Y, Gu J. Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer. World J Gastrointest Surg 2021; 13(12): 1567-1583 [DOI: 10.4240/wjgs.v13.i12.1567] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Nava-Tapia DA, Cayetano-Salazar L, Herrera-Zúñiga LD, Bello-Martínez J, Mendoza-Catalán MA, Navarro-Tito N. Brazilin: Biological activities and therapeutic potential in chronic degenerative diseases and cancer. Pharmacol Res 2021;175:106023. [PMID: 34883212 DOI: 10.1016/j.phrs.2021.106023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
11 Chen C, Xu T, Qiu X, Xie S, You Z, Hu Y, Zheng Y, Liang Z, Huang C, Chen T, Li L, Liu J, Fei Z. Selectively recommend 18F-FDG PET/CT for patients with de novo nasopharyngeal carcinoma in endemic areas. Radiat Oncol 2021;16:229. [PMID: 34838075 DOI: 10.1186/s13014-021-01954-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Huang C, Yang X. [Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2021;24:777-83. [PMID: 34802209 DOI: 10.3779/j.issn.1009-3419.2021.102.40] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Schneider G, Wirth M, Keller U, Saur D. Rationale for MYC imaging and targeting in pancreatic cancer. EJNMMI Res 2021;11:104. [PMID: 34637026 DOI: 10.1186/s13550-021-00843-1] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Ruggeri B. Cancer 2021: New therapeutic approaches for the treatment of cancer - building on advances in cancer biology and the molecular genetics of cancer. Curr Opin Pharmacol 2021;60:341-5. [PMID: 34534753 DOI: 10.1016/j.coph.2021.08.010] [Reference Citation Analysis]
15 Schilsky RL. 'Strategic' development of precision cancer medicine in the United States. Mol Oncol 2021;15:1747-9. [PMID: 34053185 DOI: 10.1002/1878-0261.13023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Lawal B, Lee CY, Mokgautsi N, Sumitra MR, Khedkar H, Wu ATH, Huang HS. mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2',4'-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications. Front Oncol 2021;11:656738. [PMID: 33842373 DOI: 10.3389/fonc.2021.656738] [Cited by in Crossref: 6] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]